The Final, Controversial Frontier
At the most ambitious end of this trend, we find the world of genetic technology. This is where things get truly transformative. Companies like CRISPR Therapeutics are working on technologies that could, in theory, edit genetic defects at their source. While the immediate focus is on treating severe diseases, one doesn’t need a wild imagination to see the future possibilities for human enhancement.
Of course, this is the highest-stakes part of the industry. It’s fraught with ethical questions and immense regulatory hurdles. The path from a lab to a marketable therapy is long and punishingly expensive. The risks are substantial, but the potential rewards, for both humanity and investors, are equally profound. For those looking to gain exposure to this sprawling and complex theme, a diversified approach might be sensible. A collection of companies like the ones in the Bio-Hacking Revolution basket could offer a way to tap into the trend without betting the farm on a single, high-risk venture.
Investing always carries risk, and this sector is certainly no exception. The path forward for these technologies is not guaranteed. However, with aging populations and a younger generation that is perfectly comfortable trading data for insights, the underlying demand for human optimisation seems unlikely to fade away.
